Stock Analiz

Oragenics Inc. OGEN

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.20Market cap $906903
Open the interactive analysis →

Oragenics Inc. (OGEN) is a healthcare company listed in the US with a market value of about $906903.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -1572%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 99% below the current price.

About Oragenics

Oragenics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $939926 in 2014 to $37653 in 2023, a decline of about 30.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 3121% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−99%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-27928.0%
ROIC (5-yr avg.)-1572.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue——$37653$131521$86987——$0$0$0
Net income-$10M-$11M-$21M-$14M-$16M-$26M-$16M-$10M-$7M-$7M
Free cash flow———-$15M-$14M—-$13M-$9M—-$7M
EPS (diluted)$-2.28$-23.94$-137.70$-106.65$-2.10$-7.05$-5.55$-13.05$-20.55$-23.55
Net margin——-54858.1%-10864.0%-18062.0%—————
ROIC-108.5%-7151.3%-473.1%-83.6%-45.7%-118.6%-68.9%-47.6%-106.4%-288.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Oragenics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 99% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Oragenics pay a dividend?

Not currently.

Is Oragenics a good stock to buy?

We do not give buy or sell advice. Oragenics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.